Compare Illumina, Inc. (ILMN) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oxford Lane Capital Corp — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Oxford Lane Capital Corp trades at $8.86 (market cap $866.15M). The key difference: Illumina, Inc. is far larger — about 32.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 27.06% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | OXLC | |
|---|---|---|
Market Cap | $27.94B | $866.15M |
Sector | Health | Financials |
52-Week High | $194.33 | $19.90 |
52-Week Low | $91.00 | $8.15 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 27.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
OXLC trades at $8.87, up 1.14% today, but faces a bearish technical outlook with negative moving averages and oscillators. The stock shows mixed fundamentals with a low P/B of 0.83 but alarming profitability metrics including a -39.16% ROE and three consecutive quarterly EPS misses. Recent news highlights concerns over its 24% dividend yield sustainability and a sharp net asset value decline reported in May 2026.
The outlook is cautious due to deteriorating earnings, high dividend risks, and negative cash flow from operations. While the P/B ratio suggests potential undervaluation, significant headwinds from poor ROE, volatile revenue, and bearish analyst sentiment outweigh opportunities. Investors should prioritize risk management amid ongoing financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
